Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, Fuchs D
community and clinical sources describe dermatological monitoring for these changes, especially with long-term use Injection site darkening localized hyperpigmentation Mood changes irritability reported by some during loading Managing nausea: community sources commonly describe beginning at 100-250 mcg, injecting before bed on an empty stomach, using anti-nausea medication (ondansetron) when needed, and escalating the dose gradually
This is typically done when FDA-approved drugs dont work, often because of allergies, delivery methods or dosage strengths
After treatment, some patients notice an improvement in their skin tone
They bind firmly to plasma proteins and are slowly excreted in the urine